Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report

The introduction of new monoclonal antibodies has become an integral part of the treatment of malignant tumors.Brentuximab vedotin (Adcetris®) – anti-D30 monoclonal antibody conjugated with monomethyluristatin E – has become a new drug registered since February 2016 in the Russian Federation (SGN-35...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Semenova, P. A. Zeynalova, M. S. Nikitina, M. I. Akhmedov
Format:	Article
Language:	Russian
Published:	ABV-press 2019-01-01
Series:	Онкогематология
Subjects:	brentuximab vedotin (adcetris®) relapse of anaplastic large cell lymphoma eosinophilia tumor lysis syndrome
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/320
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

PRIMARY PALATAL ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: RARITY TREATED SUCCESSFULLY WITH BRENTUXIMAB VEDOTIN
by: Müjgan Çözeli, et al.
Published: (2024-12-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy
by: Andrea Marcellusi, et al.
Published: (2025-04-01)

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas
by: Gen Hasegawa, et al.
Published: (2025-01-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

Hodgkin Lymphoma Treatment With Brentuximab Vedotin in a Patient With HIV, Liver Failure, and Anemia Without Transfusion
by: Ellen Marin, et al.
Published: (2025-02-01)

Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
by: Carrie van der Weyden, et al.
Published: (2025-06-01)

SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS
by: A. S. Kolbin, et al.
Published: (2017-05-01)

Neoadjuvant Immunotherapy and De-escalation of Surgery in Locally Advanced Breast Implant-associated Anaplastic Large Cell Lymphoma
by: Marzia Salgarello, et al.
Published: (2025-01-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials
by: Yue Yang, et al.
Published: (2025-07-01)

Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study
by: Zhiqiang Zhao, et al.
Published: (2025-01-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient
by: Adela Della Marina, et al.
Published: (2025-06-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

Hematopoietic Stem Cell Transplantation and High Dose Chemotherapy in Recurrent and/or Chemotherapy Resistant Hodgkin Lymphoma Cases: A Single Center Experience
by: Yöntem Yaman, et al.
Published: (2021-05-01)

A Rare Case of Anaplastic Lymphoma Kinase-negative Anaplastic Large Cell Lymphoma Presenting as Right Heart Failure
by: U. Harikishore, et al.
Published: (2025-01-01)

Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
by: Astrid Pavlovsky, et al.
Published: (2024-12-01)

Therapeutic potential of brentuximab vedotin in breast cancer and lymphoma via targeted apoptosis and gene regulation
by: Abeer Ezzat, et al.
Published: (2025-01-01)

Primary Breast Anaplastic Large-Cell Lymphoma
by: Min-Hong Wang, et al.
Published: (2023-10-01)

Overcoming Resistance in Relapsed Anaplastic Large-Cell Lymphoma, ALK-Positive (Literature Review and Clinical Experience)
by: YuE Vinogradova, et al.
Published: (2019-03-01)

Case Report: Vanishing bile duct syndrome in Hodgkin’s lymphoma: a case highlighting jaundice and lymphadenopathy as early clues
by: Shiyu Ma, et al.
Published: (2025-05-01)

Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
by: I. N. Dyakov, et al.
Published: (2022-07-01)

Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre studyResearch in context
by: Yu-Jia Huo, et al.
Published: (2025-05-01)

Differentiated, immunobased approach of anaplastic large cell lymphoma treatment in children and adolescents: literature review and protocol ALCL-NII DOG-2003 results
by: A. S. Volkova, et al.
Published: (2023-05-01)

Modern Aspects of Diagnosis and Treatment of Anaplastic Large Cell Lymphoma in Children (Literature Review)
by: AS Levashov, et al.
Published: (2016-04-01)

MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
by: E. V. Chernyshova, et al.
Published: (2017-01-01)

Anaplastic Large Cell Lymphoma with Generalized Skin Lesion in Childhood: Clinical Case
by: Timur T. Valiev, et al.
Published: (2020-12-01)

ALK-negative anaplastic large-cell lymphoma diagnosed on liver biopsy in a child presenting with nonresolving pyrexia
by: Aanchal Kakkar, et al.
Published: (2019-01-01)

Breast implant-associated anaplastic large-cell lymphoma: a systematic literature review
by: Daniel Sundfeld Spiga Real, et al.
Published: (2019-12-01)

Impact of CD3 expression on outcome in pediatric anaplastic large cell lymphoma
by: Ahmed Salah, et al.
Published: (2025-05-01)

Successful treatment of post chemotherapy esophageal cicatricial atresia in a pediatric patient with anaplastic large cell lymphoma through minimally invasive esophagectomy: a case report
by: Yuto Hozaka, et al.
Published: (2021-02-01)

SYSTEMATIC REVIEW: ANAPLASTIC LARGE CELL LYMPHOMA FOLLOWING BREAST IMPLANT SURGERY
by: Kezia Eveline, et al.
Published: (2023-06-01)

Implant-associated anaplastic large T-cell lymphoma (BIA-ALCL): case report
by: Antônio de Pádua Peppe, et al.
Published: (2024-07-01)

Corrigendum: Impact of CD3 expression on outcome in pediatric anaplastic large cell lymphoma
by: Ahmed Salah, et al.
Published: (2025-06-01)

Recurrent primary pulmonary anaplastic B-cell lymphoma in a 35-year-old patient treated with radical resection: A case report.
by: George Bashour, et al.
Published: (2025-03-01)